Inovio Pharmaceuticals (NASDAQ:INO) Trading Down 8.8%

Inovio Pharmaceuticals, Inc. (NASDAQ:INOGet Rating) traded down 8.8% during mid-day trading on Tuesday . The company traded as low as $2.07 and last traded at $2.07. 84,324 shares were traded during trading, a decline of 98% from the average session volume of 5,040,164 shares. The stock had previously closed at $2.27.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. StockNews.com raised Inovio Pharmaceuticals to a “sell” rating in a report on Monday, May 23rd. Royal Bank of Canada assumed coverage on Inovio Pharmaceuticals in a report on Tuesday, July 19th. They set a “sector perform” rating and a $4.00 price target on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Wednesday, August 17th. One analyst has rated the stock with a sell rating and six have issued a hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $5.75.

Inovio Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.06, a current ratio of 3.18 and a quick ratio of 3.18. The stock has a market cap of $498.80 million, a price-to-earnings ratio of -1.24 and a beta of 0.82. The stock’s 50-day moving average is $2.22 and its 200 day moving average is $2.48.

Inovio Pharmaceuticals (NASDAQ:INOGet Rating) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.18). Inovio Pharmaceuticals had a negative net margin of 16,775.78% and a negative return on equity of 94.19%. The firm had revenue of $0.78 million during the quarter, compared to analyst estimates of $0.52 million. During the same quarter in the previous year, the business earned ($0.39) EPS. Inovio Pharmaceuticals’s revenue for the quarter was up 187.5% on a year-over-year basis. As a group, analysts predict that Inovio Pharmaceuticals, Inc. will post -1.39 earnings per share for the current fiscal year.

Insider Activity

In other news, Director David B. Weiner sold 11,875 shares of Inovio Pharmaceuticals stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $2.66, for a total transaction of $31,587.50. Following the completion of the sale, the director now directly owns 892,625 shares in the company, valued at approximately $2,374,382.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 3.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. State Street Corp increased its stake in shares of Inovio Pharmaceuticals by 38.4% during the 2nd quarter. State Street Corp now owns 32,195,674 shares of the biopharmaceutical company’s stock worth $55,699,000 after purchasing an additional 8,927,746 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Inovio Pharmaceuticals by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 11,247,922 shares of the biopharmaceutical company’s stock worth $40,381,000 after purchasing an additional 208,609 shares in the last quarter. Wasatch Advisors Inc. increased its stake in shares of Inovio Pharmaceuticals by 37.3% during the 4th quarter. Wasatch Advisors Inc. now owns 4,926,125 shares of the biopharmaceutical company’s stock worth $24,581,000 after purchasing an additional 1,338,489 shares in the last quarter. Rafferty Asset Management LLC increased its stake in shares of Inovio Pharmaceuticals by 4.6% during the 2nd quarter. Rafferty Asset Management LLC now owns 2,071,803 shares of the biopharmaceutical company’s stock worth $3,584,000 after purchasing an additional 91,978 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Inovio Pharmaceuticals by 5.3% in the 2nd quarter. Northern Trust Corp now owns 1,992,194 shares of the biopharmaceutical company’s stock worth $3,446,000 after acquiring an additional 100,347 shares during the period. 44.96% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

(Get Rating)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Recommended Stories

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.